Introduction
Idarucizumab is a humanized monoclonal antigen binding fragment (Fab G1-kappa) that specifically neutralizes anticoagulant effect of dabigatran 1,2 and can be used in emergency situations.
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A 79-year-old woman was admitted to an emergency department for hemoptysis and progressive asthenia. She was taking dabigatran etexilate (150 mg twice daily) for nonvalvular atrial fibrillation. On admission, her full blood count revealed a hemoglobin concentration of 80 g/L, mild leucocytosis, and a normal platelet count. Laboratory investigations showed elevated urea and creatinine levels at 40.9 mmol/L and 1,031 μmol/L respectively, associated with massive dabigatran overdose (plasma concentration 2,881 ng/mL, Hemoclot Thrombin Inhibitor, Hyphen BioMed). She received two first intravenous infusions of 2.5 g idarucizumab within 15 minutes of each other few hours after admission. Two additional injections (2 Â 2.5 g each) were performed at days 2 and 5 due to high rebound of plasma dabigatran after each reversion (►Fig. 1A) and because a kidney biopsy was then considered, although no bleeding event was observed during hospitalization. Serum and urine immunofixation (IF) were performed to exclude multiple myeloma in this context of isolated, nonregenerative normocytic anemia and renal failure. At day 5, serum IF was normal whereas urine IF showed isolated monoclonal kappa light chains (KLCs, ►Fig. 1B, black arrow). Surprisingly, no free KLC was detected (►Fig. 1B) and serum free light chain ratio was normal. Urine IF was repeated daily until progressive disappearance of monoclonal KLC
Bone marrow aspiration excluded hematologic malignancies.
The patient was diagnosed with end-stage renal disease and referred to a dialysis center. Anticoagulation was resumed with warfarin. Her last creatinine clearance estimation performed 14 months ago was of 38.5 mL/min (Cockcroft-Gault) and confirmed chronic impaired kidney function. This underlines the importance of regular assessment of renal function in patients receiving dabigatran and of a dose reduction according to the label recommendation in the case of renal impairment.
Idarucizumab, dabigatran, and idarucizumab-dabigatran complexes are mainly excreted in urine. 4 Thus, idarucizumab can be detected on urine IF where it reacts with anti-KLC antibody, but not with anti-gamma heavy chain antibody because it lacks the two heavy chains composing Fc portion. Idarucizumab clearance is reduced in the case of renal impairment, leading to increased half-life and sustained urine excretion. However, one single injection of 5 g idarucizumab was insufficient to neutralize dabigatran. This case also illustrates our previous findings that an initial dabigatran plasma level !200 ng/mL before idarucizumab injection could predict dabigatran plasma rebound.
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